Technical Analysis for HARP - Harpoon Therapeutics, Inc.

Grade Last Price % Change Price Change
A 23.01 0.09% 0.02
HARP closed up 0.09 percent on Friday, March 8, 2024, on 4.63 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Mar 25
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 118.10%
Wide Bands Range Expansion 118.10%
Gapped Up Strength 118.10%
20 DMA Support Bullish 114.85%
Wide Bands Range Expansion 114.85%
20 DMA Support Bullish 118.52%
Wide Bands Range Expansion 118.52%
Down 3 Days in a Row Weakness 118.52%
Down 4 Days in a Row Weakness 118.52%
Down 5 Days in a Row Weakness 118.52%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Disease Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Prostate Cancer Ovarian Cancer Small Cell Lung Cancer Multiple Myeloma Proteins Treatment Of Ovarian Cancer Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer Mesothelin

Is HARP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.21
52 Week Low 3.11
Average Volume 1,430,201
200-Day Moving Average 10.84
50-Day Moving Average 20.95
20-Day Moving Average 22.76
10-Day Moving Average 22.96
Average True Range 0.19
RSI (14) 82.67
ADX 69.3
+DI 47.00
-DI 6.50
Chandelier Exit (Long, 3 ATRs) 22.63
Chandelier Exit (Short, 3 ATRs) 22.90
Upper Bollinger Bands 23.25
Lower Bollinger Band 22.28
Percent B (%b) 0.75
BandWidth 4.26
MACD Line 0.58
MACD Signal Line 0.75
MACD Histogram -0.1692
Fundamentals Value
Market Cap 389.98 Million
Num Shares 16.9 Million
EPS -8.62
Price-to-Earnings (P/E) Ratio -2.67
Price-to-Sales 10.19
Price-to-Book 83.79
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.06
Resistance 3 (R3) 23.05 23.04 23.05
Resistance 2 (R2) 23.04 23.03 23.04 23.04
Resistance 1 (R1) 23.02 23.02 23.03 23.03 23.04
Pivot Point 23.01 23.01 23.01 23.01 23.01
Support 1 (S1) 22.99 23.00 23.00 23.00 22.98
Support 2 (S2) 22.98 22.99 22.98 22.98
Support 3 (S3) 22.96 22.98 22.97
Support 4 (S4) 22.97